BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26384552)

  • 1. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Endocrine; 2016 Oct; 54(1):129-138. PubMed ID: 27179656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-126 targeting PIK3R2 promotes rheumatoid arthritis synovial fibro-blasts proliferation and resistance to apoptosis by regulating PI3K/AKT pathway.
    Gao J; Zhou XL; Kong RN; Ji LM; He LL; Zhao DB
    Exp Mol Pathol; 2016 Feb; 100(1):192-8. PubMed ID: 26723864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway.
    Nie ZC; Weng WH; Shang YS; Long Y; Li J; Xu YT; Li Z
    Int J Clin Exp Pathol; 2015; 8(5):4745-54. PubMed ID: 26191164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway.
    Qu Y; Wu J; Deng JX; Zhang YP; Liang WY; Jiang ZL; Yu QH; Li J
    Oncotarget; 2016 Nov; 7(45):74217-74226. PubMed ID: 27729613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2.
    Qu Y; Zhang YP; Wu J; Jie LG; Deng JX; Zhao DB; Yu QH
    J Cell Physiol; 2019 Aug; 234(10):17663-17676. PubMed ID: 30912120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-618 modulates cell growth via targeting PI3K/Akt pathway in human thyroid carcinomas.
    Yi L; Yuan Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E186-9. PubMed ID: 27453421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
    Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
    J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-107 inhibits gastric cancer cell proliferation and metastasis by targeting PI3K/AKT pathway.
    Cheng F; Yang Z; Huang F; Yin L; Yan G; Gong G
    Microb Pathog; 2018 Aug; 121():110-114. PubMed ID: 29715534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
    Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
    Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
    Wu YC; Li SY; Jia YF
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways.
    Wei ZJ; Tao ML; Zhang W; Han GD; Zhu ZC; Miao ZG; Li JY; Qiao ZB
    Int J Clin Exp Pathol; 2015; 8(5):4481-91. PubMed ID: 26191138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-122 exerts anti-proliferative and apoptotic effects on nasopharyngeal carcinoma cells via the PI3K/AKT signaling pathway.
    Cheng C; Xiaohua W; Ning J; Dan Z; Chengyun Y; Lijun Z; Li Y; Shengfu H; Hong J; He X
    Cell Mol Biol (Noisy-le-grand); 2018 Oct; 64(13):21-25. PubMed ID: 30403591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase/Akt signalling pathway.
    Guo J; Xu L; Teng X; Sun M
    Int J Mol Med; 2017 Nov; 40(5):1435-1443. PubMed ID: 28901375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram/Cu Kills and Sensitizes
    Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.